Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0CQUKB)
| ADC Name |
CAN016
|
|||||
|---|---|---|---|---|---|---|
| Organization |
Canwell Biotech (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
4(2+2)
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
Exatecan; MMAE
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)+Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC